−Removed: Our head office and operations are located at 545, Promenade Centropolis,
−Removed: Suite 100, Laval, Québec, Canada, H7T 0A3 and our research and development and quality control laboratory is located at
−Removed: Espace Lab, 2650 Maximilien-Chagnon, Sherbrooke, Québec, Canada, J1E 0M8.
+Added: Our head office and operations are located at 3009 boul.
+Added: de la Concorde
+Added: East, Suite 102, Laval, Québec, Canada H7E 2B5 and our research and development and quality control laboratory is located at Espace
+Added: Lab, 2650 Maximilien-Chagnon, Sherbrooke, Québec, Canada, J1E 0M8.
We currently lease our office and laboratory space.
−Removed: We do not own our own manufacturing facility for the production of CaPre;
−Removed: however, we do own the proprietary equipment for producing
−Removed: the API and drug product.
−Removed: We currently do not have plans to develop our own manufacturing facility.
−Removed: However, this could change
−Removed: in the foreseeable future, as we consider the most cost-effective approaches to producing CaPre while ensuring the highest level
−Removed: We currently depend on third party suppliers and manufacturers to produce our required RKO and drug substance and products.
−Removed: If CaPre is approved for distribution by the FDA, we initially expect to rely on cGMP-compliant third parties to manufacture NKPL66,
−Removed: which is the API in CaPre, and to encapsulate, bottle and package clinical supplies of CaPre.
+Added: own our own manufacturing facility to produce CaPre;
+Added: however, we do own the proprietary equipment for producing the related active pharmaceutical
+Added: ingredient, or API, and drug product.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.